Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
The spot makes lofty claims about weight-loss drugs offered by the telehealth company Hims & Hers, but says little about ...
Exclusive: ASA calls number of parallel probes ‘significant’ and describes tackling issue as ‘priority’ after it issued ...
Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results